BioPorto

Share Issue/Capital Change • Sep 21, 2012

On August 23, 2012, the Board of BioPorto decided to partially exercise the
authorization under article 16b of the Company Articles to carry out a cash
issue, private placement to a limited number of investors, see company
announcement no. 15, August 23, 2012. On today’s date, the Board has decided
to allocate the shares to a few retail investors. The issue is expected to be
finally carried out early October.

The allocation is made by the issuance of 1,500,000 new shares at DKK 3.00 each
equivalent to a nominal value of DKK 4,500,000. The new shares equate to 3.3%
of BioPorto's registered share capital before the capital increase. The new
shares carry the same rights as the existing shares.

The subscription price is 250, which equates to DKK 7.50 per share at a nominal
value of DKK 3.00. The subscription price exceeds the weighted average price
over the ten trading days preceding the Board's decision on August 23, 2012.
The issue provides BioPorto with gross proceeds of DKK 11,250,000, from which
transaction costs budgeted at DKK 600,000 will be deducted. The net proceeds
will thus be in the range of DKK 10,650,000.

When the issue is completed, the company will arrange for the inclusion of the
new shares for trading on NASDAQ OMX Copenhagen. After registration of the
1,500,000 new shares with a nominal value at DKK 3.00 each, BioPorto’s total
nominal share capital will amount to DKK 139,949,052 consisting of 46,649,684
shares each with nominal value DKK 3.00.

Use of proceeds

The share issuance will re-establish the company’s equity capital, and proceeds
will be used to the daily operation of the company and the FDA-studies. Future
financing of the daily operation of the company and debt obligations will be
secured by increasing operating income primary from The NGAL Test ™.

     For further information, please contact:

     Frank Harder, CFO

     Christina Thomsen, Investor Relations

     Telephone +45 4529 0000, e-mail investor@bioporto.com